BACKGROUND: About 50% of patients with uveal melanoma (UM) develop metastases during the course of their disease. We analyzed serum levels of Growth Differentiation Factor-15 (GDF-15), with the aim of identifying patients with early metastases. METHODS: GDF-15 concentration was measured using an enzyme-linked immunosorbent assay (ELISA) in serum samples from 188 UM patients (170 patients without metastases; 18 patients with clinically detectable metastases) and 18 healthy control individuals. Data were analyzed with respect to differences between patients with and without clinically detectable UM metastases. GDF-15 serum levels were further analyzed with regard to significant patient and tumor characteristics as revealed by histology and multiplex ligation-dependent probe amplification (MLPA) to determine chromosome 3 copy number. GDF-15 expression in UM was investigated by immunohistochemistry. RESULTS: Patients with clinically detectable metastases had significantly higher GDF-15 serum levels compared to those without clinically detectable metastases as well as to healthy individuals (ANOVA; p < 0.001). GDF-15 concentrations in UM patients with overt clinically detectable metastases were significantly higher than those in UM patients with a second malignancy in remission but without clinically detected UM metastases (ANOVA; p < 0.001). No association between serum concentration of GDF-15 and clinical, pathological, and genetic features was observed. GDF-15 protein was only expressed in a minority of UM cells in most tumors. CONCLUSIONS: Our data suggest that GDF-15 can be used as a serum marker for the diagnosis of metastases in UM patients. Further data collection and analysis are necessary to evaluate a possible prognostic role of GDF-15 in predicting early metastases.
BACKGROUND: About 50% of patients with uveal melanoma (UM) develop metastases during the course of their disease. We analyzed serum levels of Growth Differentiation Factor-15 (GDF-15), with the aim of identifying patients with early metastases. METHODS:GDF-15 concentration was measured using an enzyme-linked immunosorbent assay (ELISA) in serum samples from 188 UM patients (170 patients without metastases; 18 patients with clinically detectable metastases) and 18 healthy control individuals. Data were analyzed with respect to differences between patients with and without clinically detectable UM metastases. GDF-15 serum levels were further analyzed with regard to significant patient and tumor characteristics as revealed by histology and multiplex ligation-dependent probe amplification (MLPA) to determine chromosome 3 copy number. GDF-15 expression in UM was investigated by immunohistochemistry. RESULTS:Patients with clinically detectable metastases had significantly higher GDF-15 serum levels compared to those without clinically detectable metastases as well as to healthy individuals (ANOVA; p < 0.001). GDF-15 concentrations in UM patients with overt clinically detectable metastases were significantly higher than those in UM patients with a second malignancy in remission but without clinically detected UM metastases (ANOVA; p < 0.001). No association between serum concentration of GDF-15 and clinical, pathological, and genetic features was observed. GDF-15 protein was only expressed in a minority of UM cells in most tumors. CONCLUSIONS: Our data suggest that GDF-15 can be used as a serum marker for the diagnosis of metastases in UM patients. Further data collection and analysis are necessary to evaluate a possible prognostic role of GDF-15 in predicting early metastases.
Authors: Karijn M S Verschueren; Carien L Creutzberg; Nicoline E Schalij-Delfos; Martijn Ketelaars; Floor L L Klijsen; Barbara I Haeseker; Sabine M B Ligtenberg; Jan E E Keunen; Corrie A M Marijnen Journal: Radiother Oncol Date: 2010-04-21 Impact factor: 6.280
Authors: David A Brown; Robyn L Ward; Philip Buckhaults; Tao Liu; Katharine E Romans; Nicholas J Hawkins; Asne R Bauskin; Kenneth W Kinzler; Bert Vogelstein; Samuel N Breit Journal: Clin Cancer Res Date: 2003-07 Impact factor: 12.531
Authors: Dong Hoon Lee; Young Yang; Soon Jung Lee; Kun-Yong Kim; Tae Hyeon Koo; Sun Mi Shin; Kyu Sang Song; Young Ho Lee; Yung-Jin Kim; Jung Joon Lee; Inpyo Choi; Jeong-Hyung Lee Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Yasmin Husaini; Glen P Lockwood; Trung V Nguyen; Vicky Wang-Wei Tsai; Mohammad G Mohammad; Pamela J Russell; David A Brown; Samuel N Breit Journal: PLoS One Date: 2015-02-19 Impact factor: 3.240
Authors: Martina Angi; Helen Kalirai; Samuel Prendergast; Deborah Simpson; Dean E Hammond; Michele C Madigan; Robert J Beynon; Sarah E Coupland Journal: Oncotarget Date: 2016-08-02